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Current Cancer Diagnostics
1.1 Cancer in the U.S.
The American Cancer Society (ACS) recently estimated 562,000

American deaths were due to cancer in 2009.i Behind heart disease, cancer is the
second-most common cause of death in the U.S; it is responsible for about one in
every four American deaths. In the same report, the ACS reported that there were
1.48 million new cancer cases diagnosed in the U.S. in 2009—all with varying
prognoses from early (stage I) to advanced (stage IV).i In the past three decades,
the prognoses for 5-year survival across patients diagnosed with cancers have
improved from 50 to 66%.i These statistics reflect progress in early diagnosis and
improved treatments. However, given different treatment protocols, concomitant
illnesses, and biological differences among individuals, the survival rate for one
in every three cancer patients remains at less than five years.
1.2 Cancer
Cancer, also called malignant neoplasm, can develop from most cell types
in the human body and is characterized by unrestrained proliferation, invasion of
normal tissues, and possible metastasis to other organs. It is known to arise from
changes in the genome sequences of specific cells, such as DNA mutations or
abnormal gene formations.ii DNA base mutations include substitutions, insertions
or deletions, and rearrangements due to environmental factors or viral infections,
such as UV radiationiii and the human papilloma virusiv. Cancer accounts for more
than 100 distinct diseases, each with varying risk factors and epidemiologies.
Each type is considered to originate from a common pathogenic origin and follow
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an evolutionary process.v The cancer genome has evolved to acquire genetic
variations by random mutations and natural selection based on phenotypic
advantages. Recently, scientists have begun working to sequence the cancer
genome to determine the stomatically mutated genes and driver mutations that
contribute to cancer development.vi Research on the cancer genome will help
develop new diagnostic and treatment methods for cancer with the goal of
diagnosing cancer sooner and with better prognoses.
1.2.1

Breast Cancer

According to the ACS Cancer Facts & Figures 2009 report, aside from
skin cancer, breast cancer is the most frequently diagnosed cancer in women.i
Mutations in specific genes have been attributed to predisposition of breast
cancer. Wooster et al. identified the second known breast cancer susceptibility
gene, BRCA2, which accounts for inherited risk for developing breast cancer. Six
mutations identified in the BRCA2 gene were found to cause serious disruptions
in the open reading frame, thereby increasing a person’s susceptibility of
developing the disease.vii While the risk of developing breast cancer is increased
by genetic history, risk factors include obesity after menopause, the use of
menopause hormone therapy (MHT), and high-dose radiation to the chest during a
medical procedure.i Breast cancer is commonly detected using a type of X-ray
scanning called mammography to look for abnormalities, such as masses or
microcalcifications. Today, mammography can detect about 80-90% of breast
cancers in women without symptoms.i
In 2007, the ACS published a set of guidelines for the use of magnetic
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resonance imaging (MRI) to screen for breast cancer in patients with known
susceptibility, such as those with BRAC1 or BRCA2 gene mutations or a history
of Hodgkin disease treatment. Since mammography is less sensitive than MRI
imaging, MRI screenings may be used to detect cancer at an earlier stage in highrisk patients. MRI uses magnetic fields to produce two-dimensional images of
internal organs and tissues based on the contrast of different materials, such as fat
or muscle. To achieve high sensitivity and reliable detection in MRI screenings,
gadolinium-based contrast agents are injected intravenously. With inconsistent
reports of specificity, numerous MRI scans must be taken after the contrast agent
has been injected to distinguish between benign conditions and malignant
lesions.viii Saslow et al. found that the specificity of MRI screening was
significantly lower than that of mammography, as evidenced by the call-back
rates for additional imaging.ix Although MRI imaging has higher sensitivity than
mammography (or X-ray scanning) for early detection of breast cancer, a more
target-specific contrast agent is necessary to increase the specificity of screening
for breast cancer.
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Medicinal Application of Imaging Agents
2.1 Medical Imaging
According to the National Institutes of Health (NIH), medical imaging

refers to the process of scanning a human or animal to find clues about a medical
condition. Advances in imaging from X-rays to positron emission tomography
(PET) scans have made it possible to study the body using minimally- to
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noninvasive techniques. Higher spatial resolutions and the development of
imaging agents have made it possible for physicians and scientists to image live
subjects in real time and with reliable results.
Today, the field of molecular imaging is growing exponentially. The
ability to see specific molecular targets in vivo has the potential for imaging drug
distribution, target binding, and even receptor expression. As the field continues
to grow, the development of highly sensitive, target-specific imaging agents will
push the boundaries of diagnostic medicine for earlier disease diagnoses and
greater diagnostic confidence.
MRI was developed in the mid-20th century and then applied for medicinal
uses in 1977.x Simply stated, MRI is a noninvasive procedure that uses
radiowaves in the presence of a magnetic field to obtain information about
internal organs and tissues. The two-dimensional representation scans are taken
based on the relaxation rates of hydrogen nuclei in water contained in the tissues.
These scans are typically used for producing anatomical images for the
differentiation between normal and diseased tissues.
X-ray computed tomography (CT) scanning involves the passage of Xrays through different types of tissue. The angles at which the X-rays are
deflected and absorbed are measured to obtain a three-dimensional image based
on a collection of two-dimensional images around a single axis of rotation. CT
scans are commonly used for studying skeletal structures and the lungs.
PET scanning is a type of nuclear imaging that requires the administration
of an imaging agent containing a radioactive element, such as fluorine-18, carbon-
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11, or oxygen-15. This technique indirectly detects γ rays that result from the
positron emission associated with radioisotope decay. As the radioisotopes decay,
a positron is released, which subsequently collides with an electron, producing a γ
ray. Similar to CT scan analysis, PET images are compiled and reconstructed by
computers to give anatomic and metabolic information. PET scanning is a
versatile imaging technique that can scan various parts of the body using different
types of drugs and radioisotopes. Single-positron emission computed tomography
(SPECT) is an imaging technique similar to PET scanning; however, it directly
detects γ rays from a γ-emitting radioisotope, such as technetium-99m or indium111. Although CT and MRI scanning still provide greater resolution in imaging,
PET and SPECT scanning allow for greater sensitivity with targeting agents.
2.2 Metal-Based Bioprobes
2.2.1

Transition Metals

The radioisotopes of technetium (99mTc) and rhenium (188Re) are
commonly used in diagnostic and therapeutic agents for their physical properties,
including long half-lives and stable oxidation states. The easiest method for
delivering these radioisotopes is by chelation to bifunctional ligands, which bind
both the radioactive metal and a targeting agent.
Both technetium and rhenium are members of group 7 on the Periodic
Table and therefore have similar physical properties. The fluorescent 186Re(I) is
used in vitro to test the efficacy of ligands and for direct translation to radioactive
99m

Tc to be used in vivo. Although technetium does not have any stable isotopes,

it is commonly used as a radioisotope in diagnostic nuclear medicine as the
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metastable isomer of 99Tc, 99mTc. 99mTc can be obtained by a generator system
applying the β decay of 99Mo. The metastable isotope is a γ-emitter and has a halflife of 6 h, which is optimal for diagnostic medicine. As a β-emitter, 188Re has the
potential to be used as a therapeutic agent for treating solid tumors.xi
2.2.2

Lanthanides

The use of lanthanides in contrast agents has been explored in MRI
imaging to increase the sensitivity of MRI in comparison to PET and SPECT.
Although PET and SPECT are very sensitive types of imaging, MRI tends to be
favored because is it less expensive and less time-consuming. To enhance MRI
sensitivity, approximately 35% of MRI exams are performed with contrast agents,
including those used for imaging breast cancer. Since MRI scans measure the
relaxation of protons in water, contrast agents that are thermodynamically and
kinetically stable enhance the relaxation of water protons in the body. Low
molecular weight gadolinium(III)-based drugs are the most predominant contrast
agents in MRI imaging today due to the metal’s paramagnetic state consisting of
seven unpaired f electrons and its ability to be 8-10 coordinate. Chelating ligands
of the gadolinium-based contrast agents include the highly stable
polyaminocarboxylate motifs, such as 1,4,7,10-tetraazacyclododecaneN,N′,N′′,N′′′-tetraacetic acid (DOTA), which is known as Dotarem® (Figure 1) in
clinical use. DOTA is a stable lanthanide chelate because of its tetra-aza cycle and
carboxylic acid “arms,” which provide eight total sites for metal coordination.
The addition of a water molecule fills in the ninth coordination site in an aqueous
solution. Europium(II) is used in redox responsive contrast agents because it is
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isoelectronic to Gd(III). Today,
scientists are working toward
developing new contrast agents
that are more target-specific and
facilitate higher sensitivity in
tissue analysis.
Fluorescent
lanthanide(III) compounds are
currently being designed for
medical imaging. As

Figure 1. GdDOTA, or Dotarem®, is
currently used as a contrast agent for
MRI.

paramagnetic metals, europium(III) and terbium(III) serve as effective fluorescent
species depending on the chelating ligand. Eu(III)- and Tb(III)-based fluorescent
analogues can be used to explore binding affinities of ligands used for
gadolinium-based contrast agents with transport proteins, such as human serum
albumin (HSA). According to a study by Hamblin et al., the increase in emission
intensity of a binaphthyl chromophore containing Eu(III) was due to the efficient
energy transfer from this ligand to europium in the presence of HSA.xii This study
demonstrated that lanthanide-binding ligands can be tailored to bind transport
proteins, used as effective bioprobes for imaging, and can be directly translated to
use as gadolinium-based contrast agents. The mechanism of uptake and/or
targeted tissue of specific probes can also be studied using fluorescent
lanthanides. Vitha et al. developed two lanthanide-containing and DOTA-based
contrast agents containing phosphonate moieties for targeting bone, especially in
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areas of newly developed bone.xiii The high selectivity demonstrated by these
complexes indicates their potential as bone tumor diagnostic agents.
Eu(III) and Tb(III) possess unique fluorescent properties in aqueous
solutions including long fluorescence lifetimes (longer than common organic
fluorophores), large Stokes’ shifts, and multiple sharp emission peaks. Both ions
also retain their fluorescent properties when chelated to ligands.xiv McMahon et
al. explored the use of a supramolecular Eu(III) complex as a bioprobe for
selective imaging of microcracks in bones often caused by constant stress due to
medical conditions such as osteoporosis. The presented cyclen-based bioprobe
was found to selectively bind to bone in exposed calcium(II) sites. Emissions
were observed at 580, 595, 616, 655, and 701 nm in aqueous buffer at pH 7.4
upon excitation at 282 nm.xv Another cyclen-based Tb(III) bioprobe was
developed by Bornhop et al. to detect early-stage oral cancer lesions using a
hamster model in vivo.xvi Four emission peaks between 490 and 620 nm were
observed when the contrast agent is excited at 260 nm. The incorporation of
Eu(III) and Tb(III) in bioprobes holds extraordinary potential for the development
of target-specific bioprobes. The ligands, through which the metal ions are
chelated, provide reactive sites for conjugation of target-specific substrates.
2.3 Biocompatibilty of Bioprobes
When considering in vivo applications of bioprobes such as the transitionor lanthanide-based systems, biocompatibility must be taken into account.
Requirements for these bioprobes include solubility and stability at physiological
conditions, low toxicity, and target specificity. For MRI contrast agents, at least
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one water molecule must be bound to the metal center with rapid solvent
exchange to affect the relaxation times of the protons.
The use of metals for in vivo imaging in SPECT scanning poses a problem
with regard to heavy metal toxicity. The incorporation of strong metal-chelating
ligands, including cyclen and its conjugated derivatives allow the in vivo use of
metals in bioprobes, with decreased toxic effects. In terms of toxicity, 99mTc
decays to the stable 99Tc form, which the body may readily excrete. Lanthanidebased drugs are excreted from the body by the kidneys before the metal ions can
react with essential anions and cations in the blood.xvii The disadvantage of using
the current lanthanide-based contrast agents is the UV excitation wavelength
required to observe fluorescence is in the visible region. Using UV light in vivo
may cause radical formation and DNA damage in the patient. The metal-based
bioprobes described in this project were developed with toxicity, solubility, and
target specificity in mind. Our goal for the project was to develop bioprobes with
increased specificity for certain cancer cell types to help physicians diagnose
cancer early and reliably, for optimal patient care and higher survival rates.
2.4 Targeting Vitamin Receptors
In order to achieve target-specific delivery of imaging or therapeutic
agents for the diagnosis and treatment of cancer, genetic markers overexpressed
on the surface of the tumor cells and not on normal cells must be identified.
Target-specific bioprobes and therapeutics help eliminate the cytotoxic effects,
such as hair loss and immunosuppression, associated with nontarget specific
drugs, which tend to kill both malignant and healthy tissues. These undesirable
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side effects may be avoided by utilizing a drug carrier in the form of an essential
compound, such as a cofactor whose corresponding receptor is overexpressed by
certain cancer cells. Recently, scientists have utilized vitamin B12 (B12) as a drug
carrier because many cancer cell types, including breast cancer, have been shown
to overexpress certain B12 receptors (i.e. cubilin, megalin, and transcobalamin
II).xviii

3

Vitamin B12
3.1 Structure Description
B12, also known as cobalamin, is a highly water-soluble (10.2 mg/mL)

vitamin.xix,xx B12 is the only vitamin with a stable carbon-metal bond. It contains a
six coordinate cobalt(III) atom, bound to (1) a variable group (the β-ligand),
which is typically a cyano, hydroxyl, methyl, or adenosyl group, (2-5) a
tetradentate corrin ring, and (6) a 5,6-dimethylbenzimidazole with a
phosphoribose unit (the α-ligand), as represented in Figure 2. There are a variety
of functional groups in B12 that may be utilized for conjugation, including three
propionamide groups, three ethylamide groups, two hydroxyl groups off the
phosphoribose unit, and the β-ligand site at the Co(III) metal center.
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Figure 2. Structure of vitamin B12 (also known as
cobalamin) contains a Co(III) bound to a variable group (R
= methyl or adenosyl in biochemical form), a tetradentate
corrin ring, and a 5,6-dimethylbenzimidazole with a
phosphoribose unit.
3.2 Uptake Pathway
Despite its significance in mammalian cell growth, B12 is only produced
by bacteria, therefore, mammals must obtain B12 through the food chain or by
vitamin supplementation.xxi Since B12 must be taken in through the diet, a
selective uptake pathway has evolved in mammals for the absorption of B12.
The complex B12 uptake pathway includes three known transport proteins,
intrinsic factor (IF), transcobalamin II (TCII), and haptocorrin (HC or TCI) and
three receptors, cubilin, megalin, and TCII receptor. As represented in Figure 3,
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once B12 is ingested, it is bound to haptocorrin, a corrinoid-binding protein and
transported through the stomach, protected from the acidic environment. Once
HC-B12 is released from the stomach, it is released from HC in the intestinal
lumen and sequestered by a second protein IF (secreted by the gastric mucosa and
the pancreas). The IF-B12 complex is transported through the intestine to the
proximal ileum, where it is taken up into an enterocyte by receptor-mediated
endocytosis via the cubilin receptor, anchored by the transmembrane protein,
megalin. Following endocytosis, the cubilin-bound IF-B12 is encapsulated by an
endosome at pH = 5.5, where IF is broken down by the lysosome thereby
releasing B12. The third transport protein TCII then binds B12 to be shuttled
through the blood for cellular uptake. B12 is taken into cells either by the TCII
receptor or by the megalin receptor, which both can bind B12-bound TCII (holoTCII). According to Wuerges et al., approximately 25% of B12 binds to TCII to
form holo-TCII, while the remaining B12 recirculates bound to HC, which is taken
up and stored in hepatocytes.xxii Upon receptor-mediated endocytosis of holoTCII in a cell requiring B12, the acidic environment of the endosome causes B12 to
be released. Once the endosome is broken down by the lysosome and B12 is
released, it is subsequently methylated or adenosylated for use by the cell.
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Figure 3.. Uptake pathway of B12 is complex, requiring three transport proteins
and at least three cell receptors.
3.3 Function in the Body
B12 is an important cofactor required for certain enzymatic processes in
the mitochondria,
ochondria, cell nucleus, and cytoplasm. Processes include the conversion
of L-methylmalonyl
methylmalonyl-CoA to succinyl-CoA using L-methylmalonyl
methylmalonyl-CoA mutase
and the conversion of homocysteine to methionine using methionine synthetase.
By these processes, B12 is necessary for DNA methylation, synthesis of red blood
cells, and maintenance of the nervous system.
B12 deficiencies may occur as a result of the lack of or minimal absorption,
transportation, and/or metabolism of the vitamin. A low intracellular B12
concentration may lead to anemia, degeneration of nerve fibers, or permanent
xxiii
neurological damage, especially among infants and the elderly.xxiii,xxiv
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4

Vitamin B12 in Medical Imaging
4.1 Types of Conjugates
There is a demand for B12 in regions of enhanced proliferation, such as in

cancer cells or sites of infection. B12 can serve as a viable carrier molecule or
“Trojan Horse” for transporting cytotoxic agents and bioprobes to specific cells in
the body. The structural complexity of B12 provides a number of functional sites
for conjugation; however, to ensure a maximal binding potential of B12 transport
proteins, only a few sites can be derivatized and remain active. These sites include
the cobalt metal center, selected amides, and the 5′ hydroxyl group of the ribose
moiety.
4.1.1

Cobalt Metal Center

Scientists have created fluorescent derivatives of B12 by linking
fluorophores to the cobalt(III) metal center. Reaction of B12 with respect to the
cobalt metal center produces a photolabile carbon-cobalt (Co-C) bond, which
must be handled in dim light. Grissom et al. synthesized novel B12 conjugates
containing pendant fluorophores known as CobalaFluors for imaging B12
receptors on cancer cells. The fluorophore was conjugated to B12 through the βligand position of the aminopropyl group off of the cobalt metal center. Although
many fluorophores experience photobleaching under direct light exposure,
electronic absorption spectroscopy indicated minimal photobleaching of the
CobalaFluors under mild conditions of hydrolysis.xxv The stability of the
CobalaFluors contributes to their potential as target-specific bioprobes for
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imaging B12 receptors. However, steric interactions may inhibit the binding of the
CobalaFluors to IF and/or TCII for transport and cellular uptake.
The cyanide group of cyano-B12 may also be used as a bridge for two
metal centers, one of which is the cobalt metal center of B12. Alberto et al. used
the fac-[99mTc(CO)3]+ moiety to form a Co-C-Tc bridge for production of
radiopharmaceuticals.xxvi Biological applications of the radioactive B12 bioprobe
are contingent on the compound’s stability and affinity for the B12 transport
proteins.xxvi Binding studies of the conjugate with the different B12 transport
proteins will reveal its potential as a bioprobe for cancer cells.
4.1.2

Amide

Modification of the amide functional groups results in varying TCII
binding potentials. When converted to a carboxylic acid, the modified β position
has been shown to inhibit the binding of TCII to 2.6%, to form holo-TCII, thereby
inhibiting the conjugate’s uptake by the cell through the TCII or megalin
receptors.xxvii Conjugation through this amide group can serve as a good control
conjugate when testing intracellular fluorescence of active B12-based bioprobes.
4.1.3

Ribose

Rather than derivatizing the cobalt metal center, which has potential to
interact with the B12 transport proteins, scientists have looked to conjugate
fluorophores to the 5′ hydroxyl group of the ribose moiety of B12. Fedosov et al.
conjugated a rhodamine fluorophore derivative to B12 through the 5′ hydroxyl
group using a 1,1-dicarbonyl-di-(1,2,4-triazole) (CDT) coupling agent. The
derivative was then bound to two B12 transport proteins, TCII and IF for binding
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kinetic studies.xxviii
4.2 Drug Delivery System
This project looked at the conjugation
of a bifunctional ligand to B12 through the 5′
hydroxyl group of the ribose moiety to
optimize its uptake by cell receptors via B12
transport proteins. It followed a typical metalbased drug design (Figure 4) consisting of the
target molecule (B12) linked to a bifunctional
ligand, which was used to chelate a metal ion
such as

5

186/188

Re,

99m

Tc, Eu, or Tb.

Figure 4. Bifunctional drug
contains a target molecule
conjugated through a ligand
to a metal ion.

B12-ReBQBA
This project was inspired by the limited tissue expression of cubilin and its

putative importance for cancer cell growth. The specific aim for this project was
to exploit the use of the cubilin receptor for delivery of a B12 conjugate using the
B12 transport protein IF. Cubilin was targeted for the selective delivery and
accumulation of a new bioprobe, a B12 conjugate of rhenium BQBA (B12ReBQBA), in the cubilin expressing placental choriocarcinoma BeWo cell line.
Receptor-mediated endocytosis was utilized as a transport mechanism for
facilitating cellular entry of a rhenium fluorescent probe tethered to B12. In vitro
cytotoxicity assays and uptake studies via fluorescent confocal microscopy were
conducted on two different cell lines: human placental choriocarcinoma (BeWo)
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(cubilin (+) ) and Chinese hamster ovary (CHO) cells (cubilin (-) ).
5.1 Synthesis
5.1.1

ReBQBA

A N,N-bis(quinolin-2-ylmethyl)butane-1,4-diamine (BQBA) ligand was
synthesized as a bifunctional chelator, as shown in Figure 5, with a site for the
coordination of a metal center and a terminal amine for further conjugation.
BQBA was initially synthesized by two successive reductive aminations.
Bisquinoline-2-carboxaldehyde (100 mg, 0.636 mmol) was reacted with N-boc1,4-diaminobutane (121.7 µL, 0.636 mmol) in dichloroethane (DCE) (5 mL) at
room temperature for 1 h. The reaction was cooled to 0 °C then reduced using
sodium triacetoxyborohydride (161 mg, 0.763 mmol) for 1 h. This procedure was
repeated for the second equivalent of bisquinoline-2-carboxaldehyde (100 mg,
0.636 mmol). The reaction solution was washed three times with water (10 mL)
and once with 3.5 M sodium chloride (10 mL). The organic layer was dried over
sodium sulfate. The solvent was removed in vacuo to yield a dark red solid. The
reaction product was extracted using a 1:1 ethylacetate/hexane solution.
Purification of the reaction product was achieved by dissolving the bocBQBA complex in concentrated diethyl ether then precipitating the purified
product at -20 °C. Purity of the compound was confirmed by proton NMR and
electrospray ionization mass spectrometry (ESI-MS). The 1H NMR of boc-BQBA
was taken in deuterated chloroform at 300 MHz. 1H NMR peaks included δ =
8.135 (2H, d), 8.060 (2H, d), 7.790 (2H, d), 7.700 (4H, m), 7.510 (2H, m), 4.014
(4H, s), 3.050 (2H, m), 2.637 (2H, t), 1.60-1.80 (4H, m), and 1.20-1.50 (9H, m).
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The mass spectrum using ESI-MS included a [M + H]+ peak at 491.25 m/z with an
isotopic pattern indicative of boc-BQBA, C29H34N4O2 (M = 470.27 g/mol). The
boc protecting group was removed by adding 10% trifluoroacetic acid (TFA) in
chloroform and mixing overnight. The deprotected BQBA product was confirmed
by 1H NMR and ESI-MS.
The bifunctional chelate was labeled with rhenium(I) tricarbonyl using a
molar equivalent of the rheunium metal precursor, [Re(H2O)3(CO)3]Br, in
methanol and stirred at 60 °C for 3 h. Upon conjugation to rhenium, the 1H NMR
in deuterated chloroform indicated a downfield shift of the aromatic and bridging
CH2 protons, adjacent to the rhenium metal core. Yield was quantitative.

Figure 5. Synthetic scheme for ReBQBA.
5.1.2

B12-ReBQBA

In order to target the cubilin receptor using IF, the B12-ReBQBA
conjugate, shown in Figure 6, was designed to not interfere with the IF-cubilin
binding. This was accomplished by attaching the ReBQBA ligand to B12 through
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the 5′-hydroxyl group of the ribose moiety of B12. The cyano derivative of B12
(cyano-B12) was used for conjugation to minimize potential side reactions of the
photolabile cobalt-carbon bond.
The 5′ hydroxyl group of cyano-B12 (25.0 mg, 0.0369 mmol) was
activated with 1.2 equiv of 1,1′-carboyl-di-(1,2,4-triazole) (CDT) (4.40 mg,
0.0244 mmol) in 3 mL of dry dimethyl sulfoxide (DMSO) at 60 °C over 30 min
under inert N2 (g). The ReBQBA ligand (14.2 mg, 0.0221 mmol) previously
dissolved in 2 mL of DMSO was added dropwise to the CDT-activated B12. The
reaction solution was stirred under N2 (g) for 6 h at RT. After 6 h, the reaction
product was precipitated out of DMSO using a 4:1 diethyl ether/acetone solution.
A deep red precipitate was centrifuged at 3452 g for 10 min. The red precipitate
was dried under vacuum overnight prior to being redissolved for purification.

Figure 6. Synthetic scheme for B12-ReBQBA.
The deep red precipitate was redissolved in a 4:1 water/acetonitrile
solution and subsequently purified via reverse phase high performance liquid
chromatography (RP-HPLC). The crude B12-ReBQBA sample was purified on a
Zorbax C18 semipreparative column (250 mm x 9.4 mm) at a flow rate of 2.0
mL/min. Solvents for elution included (A) water (0.1% TFA) and (B) acetonitrile
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(0.1% TFA). The gradient was (1) 30 − 50% B over 16 min and (2) 50 − 100 % B
over 5 min. Under this method, the retention time of B12-ReBQBA was 13.7 min.
The percent yield was approximately 12–17%.
Purified B12-ReBQBA was confirmed via 1H NMR, matrix assisted laser
desorption ionization time-of-flight mass spectrometry (MALDI-TOF/MS), and
inductively coupled plasma (ICP).
A 1H NMR spectroscopic analysis of B12-ReBQBA confirmed the
proposed structure. Upon conjugation to B12, the 1H NMR taken in deuterium
oxide at 300 MHz indicated a downfield shift of the ribose aromatic protons,
adjacent to the ReBQBA.
The MALDI-TOF/MS of B12-ReBQBA displayed three sets of peaks with
the parent peak at 2022.3 m/z, consistent with the theoretical molecular mass of
[M+] = 2022.1 for C91H112CoN12O12PRe. The isotopic pattern of this parent peak
was consistent with that of the theoretical pattern of B12-ReBQBA. Fragments
consisted of the base peak at 1994.9 m/z determined to be [M+ – CO] and a set of
peaks around 1966.9 m/z determined to be [M+ – 2CO].
ICP results indicated the presence of rhenium. The carbamate linker from
B12 to ReBQBA was proven to be stable for at least 24 h between pH 5.5 and pH
7.4 by reverse phase (RP)-HPLC.
5.2 Binding to Intrinsic Factor
IF was bound to B12-ReBQBA prior to in vitro cell testing to ensure
cellular uptake by the cubilin receptor. Binding of IF to B12-ReBQBA was
monitored by electronic absorption spectroscopy, Figure 7. IF was aliquoted into
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a solution containing B12-ReBQBA in phosphate buffered saline (PBS). An
increase in absorption intensity was observed, indicating binding of IF to B12
because the symmetry of the corrin ring of B12 was reduced. Saturation of IF was
indicated by a constant absorbance intensity with additional IF aliquots.

Figure 7. Electronic absorption spectroscopy was used to follow IF
binding to B12-ReBQBA.
5.3 Cytotoxicity Studies
Conjugates were tested against BeWo and CHO cell lines to determine the
IC50 value (the concentration at which the conjugates inhibit 50% of cell growth).
The BeWo and CHO cells were cultured at 90% confluence and inoculated into a
96-well plate at ~8000 cells/well. The cells were incubated for 24 h to allow for
cell adherence. Stock solutions of BQBA, ReBQBA, B12-ReBQBA, and IF-B12ReBQBA were prepared with RPMI 1640 media. Ten-fold dilutions of the drugs
(100 µL) were added to the cells and incubated for 6 h. The drug solutions were
removed from the plates then washed with media to remove excess drugs. A 10%
Cell Counting Kit-8 (CCK-8) dye solution was prepared using RPMI 1640 media
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enriched with fetal bovine serum and penicillin streptomycin. CCK-8 dye (100
µL) was added to the plates and incubated for 24 h. The calculated IC50 values for
BeWo and CHO cells were tabulated in Table 1.
Table 1. IC50 Values (mM) Calculated for BeWo and CHO Cells after 6 hr of
Drug Exposure
IC50 (mM)
Drug
BeWo
CHO
BQBA
> 5.000
2.979 ± 0.210
ReBQBA
0.376 ± 0.028
2.627 ± 0.280
B12-ReBQBA
3.180 ± 0.258
> 5.000
IF-B12-ReBQBA
1.844 ± 0.478
4.860 ± 0.283
Uptake of BQBA, ReBQBA, and B12-ReBQBA in the BeWo cell line was
attributed to passive diffusion due to size. Additionally, the enhanced uptake of
rhenium-containing drugs may be due to the positive charge of rhenium(I), which
provides electrostatic interactions with membrane proteins, allowing for passive
diffusion of the drugs. As demonstrated by Patillo et al., the BeWo cell line has a
negative transmembrane potential of about -35 mV.xxix IC50 values were used to
confirm uptake of the IF-bound drug in the cubilin receptor-containing BeWo cell
line, and likewise, minimal uptake of the IF-bound drug in the cubilin-lacking
CHO cell line. The presence of the cubilin receptor in the BeWo cell line explains
the increased toxicity of IF-B12-ReBQBA. The higher IC50 value for the same
drug in the CHO cell line is most likely due to the inability of the CHO cells to
internalize the drug without the cubilin receptor.
5.4 Confocal Microscopy
Drug uptake experiments were performed using the BeWo cell line. The
cells were grown in RPMI 1640 with 10% fetal bovine serum and 10% penicillinstreptomycin antibiotic. They were plated at 200,000 cells/plate. The drug, 10 µM
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IF-B12-ReBQBA, was added to the plates, which were then incubated for 45 min
and 6 h to allow for sufficient uptake time. The drug was removed via pipet, and
the cells were subsequently washed three times with RPMI 1640 and 1X PBS
buffer (pH 7.4) to remove excess drug. Intracellular fluorescence was observed, as
seen in Figure 8, in the BeWo cells after 45 min drug incubation. The rapid
uptake of the large IF-bound drug is indicative of receptor-mediated endocytosis.
Optical depth scans were taken at 1 µm/slice, showing fluorescence in the middle
slices of the cell and confirming internalization of the drug after 45 min.

Figure 8. Cell binding and internalization of IF-B12-ReBQBA after 45 min
incubation with BeWo cells. Images (a) collected by a monochromatic transmitted
light photomultiplier tube (TMPT-1) and (b) after excitation at 488 nm with ~560
nm emission. (c) The merged images after simultaneous scans of (a) and (b).
Receptor-mediated endocytosis of IF-B12-ReBQBA into the BeWo cells
was further confirmed by the internalization of a pH-sensitive cyanine dye,
CypHer5E, conjugated to IF. This dye with a pKa of 7.3 fluoresces red in acidic
conditions. Once this dye is internalized by receptor mediated endocytosis, it is
encapsulated in an endosome, which has an acidic environment of pH ~5.5. The
fluorescence from the red dye combined with the green fluorescence from the IFB12-ReBQBA drug yielded a yellow color in the merged image, Figure 9. This
counterstaining experiment provides further evidence of drug uptake by cubilin-
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mediated endocytosis.

Figure 9. Receptor-mediated endocytosis was confirmed by CypHer5E endosome
counterstaining.
Competitive binding studies were performed with IF-B12-ReBQBA in the
presence of excess free B12. Excess B12 was added to the cells at concentrations of
100 µM and 10 mM and incubated for 5 min at room temperature. After 5 min, 10
µM IF-B12-ReBQBA was added to the cells, which were then incubated for 45
min. The cells were then washed and imaged under the confocal microscope at an
excitation of 488 nm. At high concentrations of free B12 (10 mM), cellular uptake
and accumulation of IF-B12-ReBQBA was inhibited.
CHO cells, which lack the cubilin receptor, were investigated for uptake
of IF-B12-ReBQBA as a control. Under the confocal microscope, there was no
observed fluorescence of IF-B12-ReBQBA in the CHO cells. This observation
indicated a lack of uptake of the drug via the IF-mediated cubilin receptor.
Since propidium iodide (PI) is known to intercalate DNA and RNA, it was
used as a counterstain to determine whether B12-ReBQBA localizes in the
nucleus. Confocal images of BeWo cells with PI, as seen in Figure 10, indicate
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aggregation of B12-ReBQBA in the cytosol as well as the nucleus. These images
suggest that the positively charged rhenium-based drug can interact with the
negatively charged DNA backbone of the cells.

Figure 10. Propidium iodide counterstaining with IF-B12-ReBQBA indicated
nuclear and cytosolic drug accumulation.
5.5 siRNA Gene Knockout of Cubilin Receptor
Small interfering RNA (siRNA) transfection was used to confirm specific
uptake of IF-B12-ReBQBA by the cubilin receptor, as indicated by cytotoxicity
assays and confocal microscopy experiments. The siRNA was used to knockdown
cubilin mRNA expression in the BeWo cells. Confocal experiments showed
illumination for both control and transfected cells, however at fluorescent
intensities of 10-fold difference. The control had a mean intensity of 4.0, while
the transfected cells had a mean intensity of 0.4. The decrease in intensity
indicated a successful knockdown of the cubilin receptor. This result also
provides further evidence that the IF-B12-ReBQBA is taken into cells by cubilin
receptor-mediated endocytosis.
5.6 Conclusions
A rhenium-based bioprobe, B12-ReBQBA, was successfully synthesized,
purified, characterized, and cell-tested for targeted drug delivery. The bioprobe
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was found to have millimolar toxicity in placental cancer cells containing the
cubilin receptor. It can also be excited at a visible wavelength to achieve emission
in the visible region. Intracellular fluorescence of B12-ReBQBA demonstrated the
potential for IF-mediated delivery of B12 conjugates by the cubilin receptor for
imaging cubilin-overexpressing malignancies. The bioprobe can be readily
switched to a radioactive derivative containing technetium-99m for in vivo studies
using SPECT scanning. This work was recently published in the Journal of
Medicinal Chemistry.xxx

6

B12-enDOTALn
As alternatives to gadolinium(III)-based contrast agents used in MRI

imaging, europium(III)- and terbium(III)-containing bioprobes were developed as
target-specific imaging agents with unique fluorescent properties. Eu(III) and
Tb(III) were chelated by a bifunctional macrocycle, DOTA, which will not only
coordinated the metal but was also conjugated to cyano-B12. These nonradioactive
B12 bioprobes will be tested on the T-47D breast cancer cell line, which
overexpresses the TCII and HC receptors. A pancreatic cancer cell line, MIA
PaCa-2, which does not express the HC receptor, will also be used to test the
bioprobes.
6.1 Synthesis of B12-enDOTA
An amino-terminal conjugate of cyano-B12 was synthesized by attaching
an ethylenediamine (en) linker to the 5′-hydroxyl group of the ribose moiety of
B12. The en linker was used to allow for carbamate linkages to be formed instead
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of weak ester bonds, which are readily hydrolyzed in aqueous environments.
The 5′ hydroxyl group of cyano-B12 (100.0 mg, 73.8 mmol) was activated
with 1.45 equiv of CDT (17.6 mg, 107.3 mmol) in 6 mL of dry DMSO at 40 °C
over 1 h under inert N2 (g), as seen in Figure 11. Ethylenediamine (4.59 µL, 68.7
mmol) and triethylamine (TEA) (9.59 µL, 68.8 mmol) were diluted in 1 mL dry
DMSO. The CDT-activated B12 was added dropwise over 30 min to the en/TEA
solution. The reaction solution was stirred under N2 (g) for 3 h at 40 °C. After 3 h,
the reaction product was precipitated out of DMSO using a 4:1 diethyl
ether/acetone solution. A deep red precipitate was spun down at 3542 g for 10
min. The red precipitate was dried in vacuo overnight prior to being reacted
further.
Assuming a yield of 100% for the B12-en reaction (106 mg, 73.8 mmol),
the metal-chelating macrocycle DOTA was conjugated to the unpurified B12-en
conjugate. Given the four reactive carboxylic acid sites of DOTA, a two
equivalent excess was activated to ensure that most of the B12-en reacted to form
the B12-enDOTA monomer.
DOTA was activated using the water-soluble coupling agent 3(ethyliminomethyleneamino)-N,N-dimethyl-propan-1-amine (EDC) with Nhydroxysulfosuccinimide (sulfo-NHS) to increase coupling efficiency. Assuming
complete conjugation, the theoretical yield for B12-en was calculated to be 106 mg
(73.8 mmol). Two equiv of DOTA (59.4 mg, 0.147 mmol) and 2.5 equivalents of
sulfo-NHS (47.9 mg, 0.221 mmol) were dissolved in 100 µM sodium phosphate
(1 mL). EDC (30.9 mg, 0.162 mmol) was dissolved separately in 100 µM sodium
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phosphate (50 µL) then added to the DOTA and sulfo-NHS solution for 20 min at
room temperature. Upon activation, B12-en dissolved in minimal 100 µM sodium
phosphate (2 mL) was added to the activated DOTA. The reaction was left
overnight at room temperature and purified by anion exchange (ANX) and RPHPLC.

Figure 11. Synthetic scheme for B12-enDOTA.
A two-step purification scheme was developed for the separation of B12enDOTA (1) from unreacted B12 and B12-en and (2) from any B12-enDOTA
oligomers. The first purification was performed using a Zorbax Sax analytical
anion exchange (ANX) column (4.6 mm x 250 mm) on a high performance liquid
chromatograph. Solvents for elution included (A) water and (B) 0.5 M sodium
chloride. At a flow rate of 1.0 mL/min, the gradient was (1) 100% A for 6 min
then (2) 100 % B for 22 min. Each peak was collected and characterized by
MALDI-TOF/MS. The ANX HPLC peak with a retention time of 13–14.5 min
had major MALDI-TOF/MS peaks with similar isotopic patterns at 1801.7 m/z,
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2770.1 m/z, and 3198.3 m/z, indicative of [B12-enDOTA – CN]+, [B12-enB12 –
CN]+, and [B12-en-DOTA-enB12 – CN]+, respectively. B12-enDOTA was
confirmed by mass spectrometry to elute off the column at a retention time of 13–
14.5 min. However, as indicated by mass spectrometry, a second purification
method was required to isolate the target product, B12-enDOTA. The target peak
was dried in vacuo then redissolved in water with 0.1% TFA to protonate the
three unbound carboxylic acid arms of DOTA to form a uniform protonation state
for C18 RP-HPLC purification.
The second purification was performed using a Zorbax C18 analytical
column (42 mm x 10 mm) at a flow rate of 1.0 mL/min. Solvents for elution
included (A) water (0.1% TFA) and (B) acetonitrile (0.1% TFA). The gradient
was 10 − 20 % B over 10 min. With this method, the retention time of B12enDOTA was 7.17 min. The MALDI-TOF/MS of this HPLC peak contained a
peak at 1801.7 m/z, consistent with the theoretical molecular mass of [M+] =
1827.9 minus the cyano group of cyano-B12, [M+ – CN] = 1801.8 m/z. The
isotopic pattern of this parent peak was consistent with that of the theoretical
pattern of B12-enDOTA, C82H120CoN20O22P, as shown in Figure 12.
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Figure 12.
2. Theoretical (left) and experimental (right) isotopic patterns of [B12enDOTA+ – CN] are equivalent.
Purity of B12-enDOTA was confirmed via 1H NMR and MALDIMALDI
TOF/MS. A 1H NMR spectroscopic analysis of the bright red solid confirmed the
proposed structure of B12-enDOTA. The 1H NMR was taken in deuterium oxide
at 300 MHz and indicated a downfield shift of the ethylene protons of DOTA. 1H
NMR peakss included δ = 7.306 (1H, s), 7.126 (1H, s), 6.517 (1H, s), 6.361 (1H,
s), and 6.111 (1H, s). The yield of B12-enDOTA
enDOTA was approximately 11%.
11%
A second peak from the HPLC had a retention time of 5.11 min. This peak
was confirmed by MALDI
MALDI-TOF/MS to be B12-enDOTA
DOTA with a proton captured
within the DOTA macrocycle, 1801.1 m/z and multiple sodium adducts at [M+ –
CN + Na] = 1823.1, [M+ – CN + 2Na] = 1845.1, [M+ – CN + 3Na] = 1867.1, and
[M+ – CN + 4Na] = 1883.0 m/z.. When heated at 65 °C, this species disappears in
i
the HPLC, indicating the proton being driven out of DOTA or loss of a sodium
adduct.
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6.2 Synthesis of B12-enDOTALn
6.2.1

B12-enDOTAEu

B12-enDOTA was reacted with europium(III) trifluoromethanesulfonate
(Eu(III) triflate) to synthesize the bioprobe, B12-enDOTAEu. Equal equivalents of
B12-enDOTA (3.75 mg, 2.05 µmol) and Eu(III) triflate (1.23 mg, 2.05 µmol) were
refluxed at 60 °C overnight in a 1:4 water/acetonitrile solution, as in Figure 13.
The reaction was monitored by RP-HPLC using the same conditions as those used
to purify B12-enDOTA.

Figure 13. Synthetic scheme of B12-enDOTAEu.
After 16 h, the reaction was purified by a Zorbax C18 analytical column
(42 mm x 10 mm) at a flow rate of 1.0 mL/min using the same conditions as those
used to purify B12-enDOTA. The retention time for B12-enDOTAEu shifted from
7.17 to 6.90 min. MALDI-TOF/MS was used to confirm the synthesis of B12enDOTAEu. A peak at 1951.0 m/z was indicative of [M+ – CN – 3H] and was
consistent with the theoretical isotopic pattern of C81H118CoN19O22PEu, as shown
in Figure 14. The loss of three protons indicated that the three unbound carboxylic
acid arms of DOTA are deprotonated. Additionally, a sodium adduct of B12enDOTAEu with the same isotopic pattern occurred at [M+ – CN + Na] = 1973.0
m/z.
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Figure 14. Theoretical (left) and experimental (right) isotopic patterns of [B12enDOTAEu+ – CN – 3H] are equivalent.
A 1H NMR was taken of the B12-enDOTAEu conjugate in D2O at 300
MHz. 1H NMR peaks included δ = 8.21 (1H, s), 6.99 (1H, s), 6.54 (2H, m), and
6.13 (1H, m). The 8.21 ppm peak is speculated
to be one of the aromatic protons of the 5,6dimethylbenzimidazole nucleotide of B12. It
appeared that this proton shifted downfield
from its original position at 7.28 ppm (HA, as
seen in Figure 15).
5).xxxi The drastic shifting of
the aromatic proton adjacent to the ssite of
conjugation and europium labeling indicates

Figure 15. Protons A-D
A of the
5,6-dimethylbenzimidazole
dimethylbenzimidazole
nucleotide of B12 experienced
shifting in the NMR upon
chelation of europium.

the successful conjugation of europium into
DOTA. The HB aromatic proton of the 5,6-dimethylbenzimidazole
dimethylbenzimidazole nucleotide,
positioned at 7.10 ppm, appeared to have shifted upfield slightly to 6.99 ppm. The
1

H NMR also indicated that there was one missing B12 aromatic proton. It has
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been speculated that the missing proton shifted to overlap the proton at 6.54 ppm.
According to Brasch et al., these protons are HC and HD, which are positioned at
6.51 and 6.36 ppm in D2O at 25 °C, respectively.xxxi The fifth aromatic proton, off
the corrin ring, remained undisturbed at 6.09 ppm. The yield of B12-enDOTAEu
was quantitative.
6.2.2

B12-enDOTATb

A similar synthetic scheme was followed for the synthesis of B12enDOTATb. B12-enDOTA was reacted with terbium(III)
trifluoromethanesulfonate (Tb(III) triflate) to synthesize the bioprobe, B12enDOTATb. Equal equivalents of B12-enDOTA (3.75 mg, 2.05 µmol) and Tb(III)
triflate (1.24 mg, 2.05 µmol) were refluxed at 60 °C overnight in a 1:4
water/acetonitrile solution, as seen in Figure 16. As with the B12-enDOTAEu
synthesis, the reaction was monitored by RP-HPLC using the same conditions as
those used to purify B12-enDOTA.

Figure 16. Synthetic scheme of B12-enDOTATb
After 16 h, the reaction was purified by a Zorbax C18 analytical column
(42 mm x 10 mm) at a flow rate of 1.0 mL/min using the same conditions as those
used to purify B12-enDOTA. The retention time for B12-enDOTATb shifted from
7.17 to 6.89 min. MALDI-TOF/MS was used to confirm the synthesis of B12-
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enDOTATb.
nDOTATb. A peak at 1957.0 m/z was indicative of [M+ – CN – 3H] and was
consistent with the theoretical isotopic pattern of C81H118CoN19O22PTb, as shown
in Figure 17.
7. The loss of three protons indicates that the three unbound carboxylic
acid arms of DOTA are deprotonated. Similar to the europium labeling of B12enDOTA,
nDOTA, a sodium adduct of B12-enDOTATb
nDOTATb with the same isotopic pattern
occurred at [M+ – CN + Na] = 1979.0 m/z. The yield of B12-enDOTATb
nDOTATb was
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Figure 17. Theoretical (left) and experimental (right) isotopic patterns of [B12enDOTATb+ – CN – 3H] are equivalent.
Unlike the 1H NMR of B12-enDOTAEu,
nDOTAEu, the aromatic protons in the 1H
NMR of B12-enDOTATb
nDOTATb were indistinguishable under the NMR conditions
trialed. The paramagnetic character of terbium accounts for this observation.
6.3 Confocal Microscopy
The T-47D
47D breast cancer cell line, containing both the HC and TCII
receptors, will be used to test th
the lanthanide(III)-containing B12 bioprobes for in
vitro fluorescence. The intensity of the fluorescence will be analyzed by confocal
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microscopy. Preliminary confocal microscopy and two-photon imaging has
indicated that a laser in the UV region (<350 nm) is required to excite the
lanthanide metals chelated in the bioprobes in order to see emission in the visible
region. This work is on going.
Previous research has indicated that a laser in the UV region (~282 nm) is
required to excite Ln(III)DOTA, without any sensitizing substituents.xxxii Pandya
et al. recently published a paper on a series of substituents that may be conjugated
to the DOTA macrocycle to increase the pi bonding within the bioprobes.
Possible substituents include the aza-thiaxanthone or tetraazatriphenylene
chromophores.xxxii

7

Future Research
7.1 B12-enDOTALn Imaging
Imaging of B12-enDOTAEu and B12-enDOTATb derivatives as well as the

EuDOTA and TbDOTA control systems on the T-47D and MIA PaCa-2 cell lines
will wait until we have access to the appropriate UV laser. In the meantime, a
DOTA derivative will be produced to sensitize the macrocycle to the chelated
lanthanide for near-visible excitation.
7.2 B12-enDOTAGd
Although GdDOTA is a current contrast agent for MRI imaging, we
propose that a B12-based GdDOTA will be a target-specific bioprobe. Targetspecificity of the contrast agent will aid in increasing the sensitivity of the scans
for more reliable results. The gadolinium metal can be chelated into the B12-
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enDOTA system in a similar reflux as the reactions with europium and terbium,
as described in Section 6.
7.3 B12-ReThiazolate
The synthesis, purification, and characterization of a water-soluble (at
physiological conditions), rhenium(I)-containing B12 bioprobe, B12-ReThiazolate,
has recently been established by the author using a similar synthetic scheme to
B12-ReBQBA sythesis (Figure 18). This probe will be used in similar applications
as the B12-ReBQBA conjugate described in detail in Section 5; however, this
water-soluble conjugate solves the solubility issue associated with B12-ReBQBA.
This bioprobe will be tested on the T-47D and MIA PaCa-2 cancer cell lines that
will be used for the lanthanide imaging work to confirm the presence of certain
B12 receptors.

Figure 18. Synthetic scheme for B12-ReThiazolate.
7.4 B12-99mTcBQBA/Thiazolate
The technetium-99m conjugates of the B12-ReBQBA and B12-
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ReThiazolate systems will be synthesized for in vivo testing. The use of 99mTc will
allow a SPECT scan to be taken of the animal model to determine the
biodistribution of the bioprobe with respect to the implanted tumor cells. This
biodistribution study will provide insight into the specificity of the bioprobe.
7.5 B12-enDOTA64Cu
In collaboration with the Department of Radiology at Washington
University in St. Louis, MO, radioactive copper-64 will be incorporated into the
B12-enDOTA construct. The 64Cu labeling will be used first for in vitro analysis in
the T-47D and MIA PaCa-2 cells to test for uptake. With successful in vitro
analyses, in vivo tests will be performed to determine the biodistribution to the
bioprobe with respect to the tumor cells.
7.6 β-Acid Derivative of B12
As a control for the B12enDOTA studies, a second B12enDOTA derivative will be
synthesized; however, the linker and
bifunctional ligand (enDOTA) will be
conjugated to the β-amide of B12
instead of the 5′ hydroxyl group of
the ribose moiety, as represented in
Figure 19. Since the β-amide is
known to participate in transport
protein binding, particularly TCII,

Figure 19. Sites of derivation in B12
include the β position, which refers to the
β-amide and the R position, which refers
to the 5′ hydroxyl group on the ribose
moiety).
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conjugation through this site will inhibit uptake of the bioprobe in cells that only
express the TCII receptor, such as the MIA PaCa-2 cells. This amide group will
be converted to an acid group using an acid, such a hydrochloric acid. The β-acid
will be purified using anion exchange and C18 columns on the RP-HPLC. The
correct β-acid will be confirmed using MALDI-TOF/MS and 13C NMR. Once the
β-acid is isolated, en will be conjugated to it using EDC and sulfo-NHS
activation. DOTA will be conjugated using a similar coupling mechanism. The
metal will be chelated to DOTA under reflux conditions. Once purified, the
labeled β-acid will be tested on the T-47D and MIA PaCa-2 cell lines. The β-acid
bioprobe is expected to be taken into the T-47D cells by HC; however, the
bioprobe is only expected to adhere to the cell surface of the MIA PaCa-2 cells
due to the presence of TCII and the absence of HC.
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